

Supplementary Table 1. Changes in HbA1c in intention-to-treat population and per-protocol population

Variable	Met+Sita	Met+Sita+Acarb	Sita+Acarb	<i>P</i> value ^a	<i>P</i> value ^b
Intention-to-treat population					
Number	65	66	34		
Week 0					
HbA1c level	8.00±0.10	7.93±0.09	7.86±0.13	0.779	0.326
Week 16					
HbA1c level	7.91±0.13	7.49±0.11	8.71±0.25	0.025	0.002
Difference vs. baseline	-0.09±0.10	-0.44±0.08	0.84±0.21	0.007	<0.001
<i>P</i> value	0.113	<0.001	<0.001		
Week 24					
HbA1c level	7.66±0.13	7.47±0.12	8.09±0.27	0.246	0.267
Difference vs. week 16	-0.25±0.05	-0.03±0.05	-0.61±0.12	0.008	0.010
<i>P</i> value	<0.001	0.429	<0.001		
Per-protocol population					
Number	52	52	22		
Week 0					
HbA1c level	8.01±0.10	7.79±0.07	7.67±0.13	0.297	0.064
Week 16					
HbA1c level	7.86±0.15	7.24±0.09	8.41±0.18	0.004	0.008
Difference vs. baseline	-0.15±0.12	-0.55±0.10	0.74±0.20	0.004	0.001
<i>P</i> value	0.049	<0.001	0.002		
Week 24					
HbA1c level	7.55±0.14	7.21±0.11	7.48±0.16	0.096	0.901
Difference vs. week 16	-0.31±0.06	-0.03±0.06	-0.93±0.68	0.031	<0.001
<i>P</i> value	<0.001	0.429	<0.001		

Values are presented as mean ± standard error.

HbA1c, glycosylated hemoglobin; Met+Sita, the group treated with metformin, sitagliptin, and acarbose placebo; Met+Sita+Acarb, the group treated with metformin, sitagliptin, and acarbose; Sita+Acarb, the group treated with metformin placebo, sitagliptin and acarbose.

^aMet+Sita vs. Met+Sita+Acarb, ^bMet+Sita vs. Sita+Acarb.